Logo image of CRY

CRYOLIFE INC (CRY) Stock Fundamental Analysis

USA - NYSE:CRY - Common Stock

17.88
+0.25 (+1.42%)
Last: 1/21/2022, 8:51:04 PM
17.88
0 (0%)
After Hours: 1/21/2022, 8:51:04 PM
Fundamental Rating

2

CRY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CRY have multiple concerns. CRY shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CRY had positive earnings in the past year.
CRY Yearly Net Income VS EBIT VS OCF VS FCFCRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 10M -10M 20M

1.2 Ratios

Industry RankSector Rank
ROA -0.16%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRY Yearly ROA, ROE, ROICCRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 2 -2 4 -4

1.3 Margins

Industry RankSector Rank
OM 4.83%
PM (TTM) -0.37%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRY Yearly Profit, Operating, Gross MarginsCRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for CRY has been increased compared to 1 year ago.
Compared to 1 year ago, CRY has a worse debt to assets ratio.
CRY Yearly Shares OutstandingCRY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M
CRY Yearly Total Debt VS Total AssetsCRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 200M 400M 600M

2.2 Solvency

CRY has an Altman-Z score of 1.67. This is a bad value and indicates that CRY is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 1.00 is on the high side and indicates that CRY has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z 1.67
ROIC/WACCN/A
WACCN/A
CRY Yearly LT Debt VS Equity VS FCFCRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.21 indicates that CRY has no problem at all paying its short term obligations.
A Quick Ratio of 2.93 indicates that CRY has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.21
Quick Ratio 2.93
CRY Yearly Current Assets VS Current LiabilitesCRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 130.77% over the past year.
CRY shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.92% yearly.
CRY shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.55%.
Measured over the past years, CRY shows a quite strong growth in Revenue. The Revenue has been growing by 11.66% on average per year.
EPS 1Y (TTM)130.77%
EPS 3Y-16.84%
EPS 5Y8.92%
EPS Q2Q%-138.46%
Revenue 1Y (TTM)40.55%
Revenue growth 3Y10.1%
Revenue growth 5Y11.66%
Sales Q2Q%10.87%

3.2 Future

The Earnings Per Share is expected to grow by 40.29% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 11.66% on average over the next years. This is quite good.
EPS Next Y-91.22%
EPS Next 2Y-45.89%
EPS Next 3Y-4.23%
EPS Next 5Y40.29%
Revenue Next Year18.02%
Revenue Next 2Y14.54%
Revenue Next 3Y12.88%
Revenue Next 5Y11.66%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CRY Yearly Revenue VS EstimatesCRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
CRY Yearly EPS VS EstimatesCRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 59.60, which means the current valuation is very expensive for CRY.
CRY is valuated expensively when we compare the Price/Earnings ratio to 27.34, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 265.53, CRY can be considered very expensive at the moment.
CRY is valuated expensively when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 59.6
Fwd PE 265.53
CRY Price Earnings VS Forward Price EarningsCRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.14
CRY Per share dataCRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

CRY's earnings are expected to decrease with -4.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)6.68
EPS Next 2Y-45.89%
EPS Next 3Y-4.23%

More info and screens

0

5. Dividend

5.1 Amount

CRY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CRYOLIFE INC

NYSE:CRY (1/21/2022, 8:51:04 PM)

After market: 17.88 0 (0%)

17.88

+0.25 (+1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)02-10 2022-02-10
Inst Owners91.55%
Inst Owner Change-0.01%
Ins Owners5.73%
Ins Owner Change0%
Market Cap703.22M
Analysts82.5
Price Target33.09 (85.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 59.6
Fwd PE 265.53
P/S 1.96
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB N/A
EV/EBITDA 23.14
EPS(TTM)0.3
EY1.68%
EPS(NY)0.07
Fwd EY0.38%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS9.11
BVpS7.92
TBVpSN/A
PEG (NY)N/A
PEG (5Y)6.68
Profitability
Industry RankSector Rank
ROA -0.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 4.83%
PM (TTM) -0.37%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.21
Quick Ratio 2.93
Altman-Z 1.67
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)130.77%
EPS 3Y-16.84%
EPS 5Y8.92%
EPS Q2Q%-138.46%
EPS Next Y-91.22%
EPS Next 2Y-45.89%
EPS Next 3Y-4.23%
EPS Next 5Y40.29%
Revenue 1Y (TTM)40.55%
Revenue growth 3Y10.1%
Revenue growth 5Y11.66%
Sales Q2Q%10.87%
Revenue Next Year18.02%
Revenue Next 2Y14.54%
Revenue Next 3Y12.88%
Revenue Next 5Y11.66%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A